J Clin Pharmacol Ther. 2023;4(1):JCPT-04-1037 | Open Access
Yunmei Wang, Jiao Yang, Yanwei Shen, Xiang wang, Guangxi Wang and Jin Yang
Objective: We have observed in previous clinical studies: the predictive performance of TLR2 for endocrine resistance was higher in HER2-positive Breast Cancer (BCa) than in other hormone receptor-positive BCa cases so, what about TLR2 expression in triple positive breast cancer cell lines (BT474)? This research aimed to evaluate the expression and establishment of drug resistance model of TLR2 in ... Read more
RESEARCH ARTICLE Updated Mar 03, 2023 PDF
J Clin Pharmacol Ther. 2023;4(1):JCPT-04-1036 | Open Access
Rubin Zareski
Achievement of sustainable economic stability and growth in the last 15 years was influenced by the absence or inconsistence of structural reforms in the major world economies. Negative or zero growth trends in the country’s GDP have significantly affected the Pharma industries, forcing them to shift and/or reduce the costs in all horizontal areas of business, affecting among ... Read more
RESEARCH ARTICLE Updated Jan 28, 2023 PDF
J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1035 | Open Access
Ferrara M, Trevisan G, Marinaro L, Accardo G, Fantino S, Alladio F, Drappero E, Tettoni M, De Vivo E, Ianniello A, De Nicolò A, D’AvolioA, Calcagno A and Bonora S
Background: Doravirine (DOR) and Rilpivirine (RPV) are the NNRTIs currently most used in the clinical setting, in dual and triple drug regimens (2DR and 3DR). Intracellular (IC) Pharmacokinetics (PK) of these drugs has not been fully elucidated. Our aim was to compare plasma PK and IC accumulation in real-life experienced patients (pts).
Methods: Pts on DOR- and RPV-including Antiretroviral (... Read more
SHORT COMMUNICATION Updated Dec 22, 2022 PDF
J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1034 | Open Access
Yu Kyong Kim, Young-Sim Choi, Won Tae Jung, Kyu-Yeol Nam, Jae Seok Roh, Youn-Woong Choi, Sang-Min Cho, Do-Hyung Ki, Tae-Wan Kim, Hye J. Lee, Su Jeong, Min Kyu Park, Ha-Yeon Kim, Ji Hyeon Lee and Jun Gi Hwang
Purpose: Proton-pump inhibitors, such as rabeprazole, are prone to degradation in stomach acid. The use of Enteric-Coated (EC) forms minimizes this problem; however, these forms have slower onset time. The Pharmacokinetics (PK) and Pharmacodynamics (PD) of rabeprazole in a Fixed-Dose Combination (FDC) tablet with sodium bicarbonate, which was used to raise the intragastric pH, and in a conventional EC tablet ... Read more
RESEARCH ARTICLE Updated Dec 20, 2022 PDF
J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1033 | Open Access
Oliva B, Gómez NA and Fernández JR
Cancer is a disease with high incidence. Other therapies as surgery and radiotherapy are also used in the treatment of this disease. However, the effect adverse and the metastasis limited the use of these therapies. Target anticancer Targeted cancer treatment is an attractive approach where drugs or other substances which targets specific molecules to block the growth and spread of ... Read more
RESEARCH ARTICLE Updated Dec 16, 2022 PDF
J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1032 | Open Access
Serdar Ferit Toprak, Muhammed Ayral and Serkan Dedeoglu
Objectives: The relationship between vitamin D and laryngomalacia is not fully known. Our study aimed to investigate whether there is any relationship between laryngomalacia and vitamin D.
Materials and methods: Thirty-two patients under one year of age with a diagnosis of laryngomalacia without any other disease were included in our study. Anamnesis, physical examination, and examination with a flexible ... Read more
SHORT COMMUNICATION Updated Dec 05, 2022 PDF
J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1031 | Open Access
Himmatrao Saluba Bawaskar and Pramodini Himmatrao Bawaskar
Rabies glycoprotein outer content of rabies viral cell wall downgrade virion infected cellular apoptosis. Cellular apoptosis inversely related to virulence of virus. Beta bungarotoxin of krait (Bungarus Caeruleus) venom molecular structure similar to the glycoprotein of the rabies virus. The antibodies or immunoglobulin against the krait venom (beta-bungarotoxin) para- specially inhibit the viral glycoprotein and upgrade the apoptosis of infected ... Read more
SHORT COMMUNICATION Updated Dec 05, 2022 PDF
J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1030 | Open Access
Samira Jafari, Mohsen Meimanatabadi, Mehdi Meimanatabadi, Hossein Meimanatabadi and Cédric Delattre
Teeth discoloration is one of prevalent aesthetic concerns resulted from intrinsic/extrinsic reasons. Bleaching process can be a valuable treatment for patients with severe discolorations, which can cause an immediate change in their teeth color. According to literature review, use of commercial products owing to their high concentration of hydrogen peroxide can lead to lessen the enamel microhardness. Regarding these ... Read more
RESEARCH ARTICLE Updated Dec 05, 2022 PDF
J Clin Pharmacol Ther. 2022;3(1):JCPT-03-1028 | Open Access
Chunggoo Kim, Hyun Soo Shim, Yujung Chang, Hyeonjoo Im and Junsang Yoo
What is known and objectives: Spinal Cord Injury (SCI) is defined for the last few decades as patients getting wheelchair bound and under medication for a lifetime [1]. Medical battery for SCI is very limited which often results in heightened frustration for the caregivers who land up with no solid solution to the condition. However, in recent times due to the ... Read more
REVIEW ARTICLE Updated Oct 03, 2022 PDF
J Clin Pharmacol Ther. 2022;3(1):JCPT-03-1027 | Open Access
Victor T Wilcox, Sarah D George, Pamela B Yang, Cruz Reyes-Vazquez and Nachum Dafny
Methylphenidate (MPD) is a psychostimulant widely used to treat ADHD. MPD consumption has increased among ordinary people as a cognitive enhancer and recreational drug across multiple age groups. Due to the close pharmacological profile it shares with cocaine and amphetamines there is concern that MPD has the potential to elicit dependence and abuse. The object of this study was to ... Read more
RESEARCH ARTICLE Updated Sep 14, 2022 PDF
J Clin Pharmacol Ther. 2022;3(1):JCPT-03-1026 | Open Access
Dafny N, Reyes-Vasquez C and Liu Y
Methylphenidate (MPD) is a CNS stimulant known for its treating behavioral disorders. The increase in its use among “normal” individuals for cognitive enhancement and recreation has become a serious public health problem. This study reveals that acute MPD exposure elicits mainly increases in neuronal and behavioral activity in dose response characteristics. Chronic exposure of MPD compared to acute (0.6, 2.5 ... Read more
RESEARCH ARTICLE Updated Sep 14, 2022 PDF
J Clin Pharmacol Ther. 2022;3(1):JCPT-03-1025 | Open Access
Xiaodong He, Youcheng Zhang, Chao Niu, Xiaogang Li, Bo Li and Ruofei Sun
Breast cancer is one of the leading causes of cancer-related mortality worldwide and is the most common malignancy in women. Breast cancer is not only highly prevalent and aggressive, but also highly susceptible to recurrence and metastasis, which greatly restricts its clinical treatment outcome. In recent years, miRNAs have been shown to be closely related to the recurrence and metastasis ... Read more
RESEARCH ARTICLE Updated Feb 16, 2022 PDF
J Clin Pharmacol Ther. 2022;3(1):JCPT-03-1024 | Open Access
Al-kuraishy HM, Al-Gareeb AI, Hussain HN and Al-Shuely AA
King Kong is a 2005 epic monster adventure movie co-authored, produced and directed by Peter Jackson. A second edition of the 1933 movie of the same title, movie stars Naomi Watts, Jack Black, Adrien Brody. Set in 1933, the movie follows the story of an ambitious director forcing his crew to travel to the mysterious Skull Island. There, they encounter prehistoric creatures living ... Read more
LETTER TO EDITOR Updated Jan 20, 2022 PDF
J Clin Pharmacol Ther. 2021;2(3):JCPT-02-1023 | Open Access
Tahmina Zahan, Morshed Nasir, Abdul Quddus Shohag, Rawshan Ara perveen, Sayma Parvin and Abdul Quddus Shohag
Background: The objective was to perceive the demographic characteristics, clinical symptoms, comorbidities, and biomarkers (hematological, inflammatory, hepatic, renal, and metabolic) of Intensive Care Unit admitted survivors and deceased patients with coronavirus and link with ABO system admitted to a tertiary level hospital in Dhaka, Bangladesh. Methods: It was a retrospective cohort, conducted in Holy Family Red Crescent Medical College Hospital, ... Read more
RESEARCH ARTICLE Updated Nov 24, 2021 PDF
J Clin Pharmacol Ther. 2021;2(3):JCPT-02-1022 | Open Access
Frank Comhaire and Jan Pen
Background and objectives: Other than the direct impact of cardiopulmonary sequelae, COVID-19 disease may cause persistent signs and symptoms describes as post-COVID syndrome or long COVID. The clinical presentation and neuroimaging aspects of patients suffering from this condition are remarkably similar to those seen in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Inflammation, immune disorder and oxidative damage ... Read more
RESEARCH ARTICLE Updated Nov 10, 2021 PDF
J Clin Pharmacol Ther. 2021;2(3): JCPT-02-1021 | Open Access
Yuji Tezuka, Osamu Sekine, Akiko Hirano, Yukako Hanada, Kayo Harada, Choka Azuma, Yukako Yamamoto, Jun Ito Kobayashi, Miki Washiyama, Masanori Iwanishi, Masao Kanamori, Akira Shimatsu and Atsunori Kashiwagi
We conducted a prospective open-label, short-term, and double-arm exploratory study to investigate changes in the skin hydration state in Japanese patients with Type 2 Diabetes Mellitus (T2DM) treated with either 50 mg ipragliflozin (a Sodium-Glucose Cotransporter-2 Inhibitor: SGLT2i) (n=8) or 50 mg sitagliptin (as a control) (n=6) 1×/day for 14 days. We performed a post-hoc analysis of reported clinical data to ... Read more
SHORT COMMUNICATION Updated Oct 27, 2021 PDF
J Clin Pharmacol Ther. 2021;2(3):JCPT-02-1020 | Open Access
Nilgun Eroglu, Ömer Akcal, Metin Cil, Hatice Mutlu Albayrak and Dilek Karagoz
Activated PI3K-Delta Syndrome (APDS) is an immunodeficiency caused by gain-of-function mutations in PIK3CD. This disease exhibits complex immune phenotypes including increased IgM, recurrent infection, and impaired vaccine responses. Patients with APDS also experience other complications including lymphoid hyperplasia, autoimmunity, increased susceptibility to herpes viruses, especially Epstein-Barr virus and cytomegalovirus, and an increased incidence of B-cell lymphoma. In this ... Read more
CASE REPORT Updated Oct 07, 2021 PDF
J Clin Pharmacol Ther. 2021;2(2):JCPT-02-1019 | Open Access
Omer Akcal, Ilke Taskirdi, Selime Ozen, Idil Akay Haci, Semiha Bahçeci Erdem, Sait Karaman, Nesrin Gulez and Ferah Genel
Autosomal recessive Agammaglobulinemia (ARA) is an uncommon type of congenital Agammaglobulinemia characterized by the absence of any of the molecules that constitutes the pre-B cell receptor complex at the B lymphocyte developmental stages. ARA is defined by profound hypogammaglobulinemia of all immunoglobulin isotypes and absence of circulating B lymphocytes. Herein, we report an atypical case of ARA with λ5/14.1 deficiency ... Read more
CASE REPORT Updated Sep 24, 2021 PDF
J Clin Pharmacol Ther. 2021;2(2):JCPT-02-1018 | Open Access
Cao yuming, Chen zhenlie, Chen huijun, Guo juanjuan, Yu xuechen and Zhang yuanzhen
Effective detection and treatment of COVID-19 is still a major challenge. However, a comprehensive and detailed description of the changes experienced by human placental immune cells after COVID-19 infection is still lacking. Here, we performed proteomic profiling of placenta from 5 Nucleic acid positive COVID-19 pregnant women and 5 control individuals. The 162 proteins showed differential expression in COVID-19 pregnant women, of which 108 ... Read more
RESEARCH ARTICLE Updated Sep 08, 2021 PDF
J Clin Pharmacol Ther. 2021;2(2):JCPT-02-1017 | Open Access
Ankit Bhardwaj
Background: Polypharmacy, contribute to increase risk of adverse drug reaction morbidity, mortality, increase length of hospital stay, hospital revisits and readmissions. We aimed to evaluate the prevalence and trends of polypharmacy and Potentially Inappropriate Medications (PIMs) in elderly patients using updates Beers Criteria 2019. We try to assess the severity of adverse drug events using modified Hartwig and Siegel scale in ... Read more
RESEARCH ARTICLE Updated Aug 06, 2021 PDF
J Clin Pharmacol Ther. 2021;2(2):JCPT-02-1016 | Open Access
Ankit Bhardwajand Sangeeta Sharma
Background: Unlike first line Antiepileptic Drugs (AEDs) specific therapeutic range for Levetiracetam (LEV) has not been defined. The present study was conducted to find the mean serum LEV levels using population pharmacokinetics and to find out the correlation with the demographic and physiological determinants (age, gender, weight and dose) and concomitant antiepileptics drugs in the north Indian population.
Methods: ... Read more
RESEARCH ARTICLE Updated Aug 06, 2021 PDF
J Clin Pharmacol Ther. 2021;2(2):JCPT-02-1015 | Open Access
Palanisamy Sivanandy and Tan Si Jie
Background: Antibiotic resistance is an alarming situation in the healthcare sector, where the practice of healthcare professionals plays a vital role in preventing antibiotics-related harm. A cross-sectional study was conducted to analyze the knowledge, attitude, perception, and practice of antibiotic use and resistance among the final year pharmacy students of a Malaysian private medical university.
Methods: A cross-sectional study was ... Read more
RESEARCH ARTICLE Updated Jul 30, 2021 PDF
J Clin Pharmacol Ther. 2021;2(1):JCPT-02-1014 | Open Access
Sharanya Shre ES, Ravi S and Ezhil Arasan R
Pharmacogenomics is a field with a futuristic goal of providing personalized medicine based on an individual’s genetic makeup. The field experiences an exponential growth of evidence and research that could enable physicians to to prescribe medicines to treat underlying conditions while enhancing the predictability of adverse reactions and efficacy of a drug for an individual. With the continued ... Read more
RESEARCH ARTICLE Updated Jul 13, 2021 PDF
J Clin Pharmacol Ther. 2021;2(1):JCPT-02-1013 | Open Access
Muniza Bai, Pratap Upadhya, Lakshmi Sandhya, Manju Rajaram and Biswajit Dubashi
Though Dasatinib is a second-generation tyrosine kinase inhibitor used for the first line therapy of CML, it is associated with the risk of pulmonary hypertension and pleural effusion. Pleural effusion due to Dasatinib is often reversible unlike pulmonary hypertension. Asymptomatic pleural effusion warrants only conservative management and regular follow up. For symptomatic effusions, dose reduction or dose interruption is recommended. ... Read more
CASE REPORT Updated Jul 07, 2021 PDF
J Clin Pharmacol Ther. 2021;2(1):JCPT-02-1012 | Open Access
Di Mascio T, Correard F, Montaleytang M, Honore S, Couderc AL, Villani P, Auquier P, Daumas A and Berbis J
Purpose: Given limited human resources in France’s healthcare system, this study aimed to identify the predictive factors of unintentional medication discrepancies (UD) (described as unintentionally changes, adds or omits medication taken by a user prior to admission) in the elderly, in order to help prioritize which patients should undergo Medication Reconciliation (MR) upon hospital admission.
Methods: A ... Read more
RESEARCH ARTICLE Updated Jul 05, 2021 PDF
J Clin Pharmacol Ther. 2021;2(1):JCPT-02-1011 | Open Access
Indu T, Sanjay S and Priyanka D
Autoimmune thyroid disease triggers because of T cells attack in immune system (in thyroid gland). AITD mainly comprises of two types, ‘Hashimoto’s thyroiditis’ (hypothyroidism) and ‘Grave’s Disease’ (thyrotoxicosis). India have ‘42 million’ people groups experiencing thyroid disease, likewise it has perceived that in contrast with men 80% women’s affect more ... Read more
REVIEW ARTICLE Updated Jun 28, 2021 PDF
J Clin Pharmacol Ther. 2021;2(1):JCPT-02-1010 | Open Access
P.G.J. Ter Horstand L.W. Mulder
To report a case of imatinib use in a vasectomized patient and the use of condoms. In September 2020, a 45 year-old- pre menopausal female contacted the Medication Pregnancy and Lactation policlinic of the Isala Clinics (MAZ, Zwolle, and The Netherlands) for advice about the medication used by her spouse. He was treated with imatinib 400 mg once daily and they were told ... Read more
CASE BLOG Updated Mar 25, 2021 PDF
J Clin Pharmacol Ther. 2021;2(1):JCPT-02-1009 | Open Access
Cunha UGV, Rocha FL, Carvalho FBCL and Duarte DB
Severe Major Depression (MD) in very elderly patients usually requires a rapid response due to an increase risk of suicide and a faster clinical deterioration. In this scenario, electroconvulsive therapy constitutes the treatment option available at present. Nevertheless, not every older depressive patient is fit for a procedure which involves anesthesia and possible cardiovascular side effects. In this context, ketamine ... Read more
CASE REPORT Updated Feb 25, 2021 PDF
J Clin Pharmacol Ther. 2021;2(1):JCPT-02-1008 | Open Access
Xia M, Meng G and Dong J
What is known and objectives: Lung cancer has become one of the leading causes of cancer-related morbidity and mortality. Oncolytic virotherapy is an emerging therapeutic modality that utilizes replication-competent viruses to destroy cancers. The aim of this study was to investigate the synergistic effect of NF-κB signaling pathway inhibitor and oncolytic measles virus vaccine against lung cancer and ... Read more
RESEARCH ARTICLE Updated Feb 11, 2021 PDF
J Clin Pharmacol Ther. 2021;2(1):JCPT-02-1007 | Open Access
Pacifici GM
Lopinavir is structurally similar to ritonavir but is 3- to 10-fold more potent against HIV-1. This agent is active against HIV-1 and HIV-2. Lopinavir is coformulated with ritonavir which is a CYP3A4 inhibitor. Ritonavir is a peptidomimetic HIV protease inhibitor and is active against HIV-1 and HIV-2. The formulation of lovirapin/ritonavir is available in tablets and in oral ... Read more
RESEARCH ARTICLE Updated Jan 11, 2021 PDF
J Clin Pharmacol Ther. 2020;1(1):JCPT-01-1006 | Open Access
Pacifici GM
Caspofungin (Cancidas®) is an echinocandin and inhibits 1,3-β-D-glucan synthesis which is an essential component of the fungal cell wall and is required for cellular integrity. Caspofungin exhibits fungicidal and fungistatic activities against Candida and Aspergillus species, respectively. Caspofungin is largely eliminated by N-acetylation, catalyzed by CYP3A4, and inhibition of this enzyme causes marked increase of Caspofungin ... Read more
RESEARCH ARTICLE Updated Dec 31, 2020 PDF
J Clin Pharmacol Ther. 2020;1(1):JCPT-01-1005 | Open Access
Asha K Rajan, Vedha pal Jeyamani S, Deepak Paul Denagaran, Franklin Jose, Nallabothula Manoj Kumar and Narendra Babu
Cabozantinib (CAB), a Tyrosine Kinase Inhibitor (TKI) is the first-line therapy for Metastatic Renal Cell Carcinoma (mRCC) updated recently. Reports on adverse reactions of CAB include cutaneous reactions in a RCC patient. Other TKI (Sunitinib) reported cases on drug induced acute interstitial nephritis. To illustrate this, we depict a case on CAB induced adverse reactions in a RCC patient after 1 ... Read more
CASE REPORT Updated Nov 20, 2020 PDF
J Clin Pharmacol Ther. 2020;1(1):JCPT-01-1004 | Open Access
Asmaa Mosselhy, MahaYousif Zein , Manal Abdelsalam and Shaimaa Abdelmalik Pessar
GDF-15 is a stress-induced cytokine of the TGF-β (transforming growth factor-β) super family, which increases during tissue injury and inflammatory states. Little is known about the relationship between Growth Differentiation Factor-15 (GDF-15), and anemia among children on regular hemodialysis.
Aim: The study aimed to evaluate the serum level of growth differentiation and factor-15 (GDF-15) and C-Reactive Protein (CRP) ... Read more
RESEARCH ARTICLE Updated Nov 12, 2020 PDF
J Clin Pharmacol Ther. 2020;1(1):JCPT-01-1003 | Open Access
Daniela Mariano Carvalho-Louro
In the practical clinical of Hepatology, the focus of daily life has been the treatment of patients with severe liver diseases, such as cirrhosis and liver cancer. Of all the liver diseases responsible for cirrhosis development, hepatitis C had made the most treatment progress. In a few years, it evolved from drugs with low efficacy and many side effects to ... Read more
LETTER TO EDITOR Updated Oct 28, 2020 PDF
J Clin Pharmacol Ther. 2020;1(1):JCPT-01-1002 | Open Access
Samir Kumar Patra
“Higher the mutation rate higher is the possibility to evolve” and “higher the possibility to evolve higher is the possibility of extinction”. I hypothesize that pharmacological acceleration of the rate of mutations in the viral progeny genomes would help to destroy the virus infectivity and/or virulence. It is clear from the history of viral diseases ... Read more
REVIEW ARTICLE Updated Oct 03, 2020 PDF
J Clin Pharmacol Ther. 2020;1(1):JCPT-01-1001 | Open Access
Nader Namazi
Due to the instability of most biomolecules during the adsorption process on a hydrophobic polymer, the polymer surface can be modified to suit proteins binding mechanism. Binding of a protein to a biomolecule involves specific interaction domains that require substrate specificity. Isolating such interaction domains and incorporating them into large polypeptide chains can provide protein-binding epitopes on the surface. These ... Read more
RESEARCH ARTICLE Updated Sep 07, 2020 PDF